Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Income (2016 - 2026)

Akebia Therapeutics has reported Operating Income over the past 10 years, most recently at -$8.6 million for Q4 2025.

  • Quarterly Operating Income rose 40.22% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Dec 2025, up 146.56% year-over-year, with the annual reading at $23.5 million for FY2025, 146.56% up from the prior year.
  • Operating Income was -$8.6 million for Q4 2025 at Akebia Therapeutics, down from $4.4 million in the prior quarter.
  • Over five years, Operating Income peaked at $34.1 million in Q2 2022 and troughed at -$79.3 million in Q2 2021.
  • The 5-year median for Operating Income is -$12.8 million (2023), against an average of -$20.9 million.
  • Year-over-year, Operating Income plummeted 1141.27% in 2024 and then skyrocketed 261.48% in 2025.
  • A 5-year view of Operating Income shows it stood at -$65.3 million in 2021, then surged by 92.55% to -$4.9 million in 2022, then soared by 128.22% to $1.4 million in 2023, then plummeted by 1141.27% to -$14.3 million in 2024, then soared by 40.22% to -$8.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Operating Income are -$8.6 million (Q4 2025), $4.4 million (Q3 2025), and $14.1 million (Q2 2025).